Compare BHFAN & MDAIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Brighthouse Financial Inc. Depositary shares each representing a 1/1000th interest in a share of 5.375% Non-Cumulative Preferred Stock Series C
Current Price
| Metric | BHFAN | MDAIW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 1400 | 78 |
| Industry | Life Insurance | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | BHFAN | MDAIW |
|---|---|---|
| Price | $12.69 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 35.6K |
| Earning Date | N/A | 02-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,264,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 44.52 |
| 52 Week Low | N/A | $0.08 |
| 52 Week High | N/A | $0.90 |
| Indicator | BHFAN | MDAIW |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 40.33 |
| Support Level | $12.48 | $0.40 |
| Resistance Level | $12.80 | $0.59 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 20.97 | 0.00 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.